Helix Announces $50 Million Series C Funding to Continue Acceleration into Clinical Population Genomics and COVID-19 Viral Surveillance

SAN MATEO, Calif.: SAN MATEO, Calif., June 3, 2021 /PRNewswire/ -- Helix, the leading population genomics and COVID-19 testing company, has closed on its Series C funding round led by existing investors Warburg Pincus, DFJ Growth, Kleiner Perkins Caufield Byers, Mayo Clinic and Temasek. The $50M round will be used...

Click to view original post